作者:Michael G. Hamilton、Catrin E. Hughes、Alison M. Irving、Christopher M. Vogels、Stephen A. Westcott
DOI:10.1016/s0022-328x(03)00260-2
日期:2003.8
The hydroboration of allyl sulfonamides (4-H3CC6H4SO2NRCH2CH=CH2: R = H, 1; Ph, 2; Bz, 3) with catecholborane (HBcat) using different rhodium catalysts has been examined using multinuclear NMR spectroscopy. Reactions give complex product distributions, regardless of the choice of catalyst, arising from a competing isomerization reaction. This isomerization reaction can be used with N-substituted allyl sulfonamides 2 and 3 to give the corresponding enamines (4-H3CC6H4SO2CH=CH2CH3), which in turn react with HBcat to give regioselective formation of one isomer (4-H3CC6H4SO2NRCH2CH2(Bcat)CH3). (C) 2003 Elsevier Science B.V. All rights reserved.
The Preparation of Certain Nitrogen-Substituted Sulfonanilides
作者:George H. Young
DOI:10.1021/ja01325a053
日期:1934.10
Total removal of an unruptured orbital hydatid cyst
作者:Cevdet Gökçek、Nuray Bayar、Zeki Buharal
DOI:10.1016/s0008-4182(01)80045-4
日期:2001.6
[EN] FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE<br/>[FR] SULFONAMIDES TRICYCLIQUES CONDENSÉS INHIBITEURS DE GAMMA-SECRÉTASE
申请人:ELAN PHARM INC
公开号:WO2007143523A2
公开(公告)日:2007-12-13
(EN) The invention provides compounds of formula (I): or pharmaceutically salts thereof, where R1, R2 and the A, B, and C-rings are as defined herein. Compounds of formula (I) are useful in treating or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds or salts of formula (I), methods of preparing the desired compunds, and methods of treating cognitive disorders, such as Alzheimer's disease, using the compounds or salts of Formula (I).(FR) La présente invention concerne des composés de formule I : ou des sels pharmaceutiquement acceptables de ceux-ci, où R1, R2 et les cycles A, B et C sont comme présentement défini. Les composés de formule I sont utiles dans le traitement ou la prévention de troubles cognitifs, tels que la maladie d'Alzheimer. L'invention concerne en outre des compositions pharmaceutiques comprenant des composés ou sels de formule I, des procédés de préparation des composés souhaités, et des procédés de traitement de troubles cognitifs, tels que la maladie d'Alzheimer, utilisant les composés ou sels de Formule(I).
<i>N</i>-ALKYLATION OF<i>N</i>-MONOSUBSTITUTED SULFONAMTOES IN IONIC LIQUIDS
作者:Yi Hu、Zhen-Chu Chen、Zhang-Goo Le、Qin-Guo Zheng
DOI:10.1080/00304940409458677
日期:2004.8
N-dimethylformamide,2.7." and xylene." This method involves harsh reaction conditions, long reaction times and low yields in organic solvents. This reaction also can be accomplished via phase-transfer catalysts process? but involves the use of organic solvents. Recently, the N-alkylation of N-monosubstituted sulfonamides via the Mitsunobu reaction has been reported? However, these conditions require the use
N-单取代磺酰胺的 N-烷基化是 Gabriel 型仲胺合成中的关键步骤,随后通过 SN 键的已知还原程序裂解磺酰胺。* 此外,磺胺类药物本身构成一类重要的药学化合物。* 然而,这种转化的可用途径有些有限。这种反应通常需要强碱,如 Na。N w 4 NaOR?KOH6等和甲醇等有机溶剂的使用?乙醇?N,N-二甲基甲酰胺,2.7." 和二甲苯。" 该方法涉及苛刻的反应条件、较长的反应时间和在有机溶剂中的低收率。这个反应也可以通过相转移催化剂过程来完成?但涉及使用有机溶剂。最近,有报道称 N-单取代磺酰胺通过光信反应进行 N-烷基化?然而,这些条件需要使用昂贵的试剂、惰性气体、有机溶剂,反应时间长,有时收率低。因此,使用简便有效的方法对 N-单取代磺酰胺进行 N-烷基化仍然是有机合成中的一个挑战。